<p>隨着澳大利亞市場接近 2025 年底，儘管華爾街的指數接近歷史高點，但市場似乎處於反思的狀態，投資者在假期前進行獲利了結，導致市場略有下滑。在這種環境下，內部持股比例高的成長型公司可能會提供吸引人的機會，因為它們在管理層與股東利益之間的潛在一致性。</p>
<h3>澳大利亞內部持股比例高的十大成長型公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股比例</strong></td>
<td><strong>收益增長</strong></td>
</tr>
<tr>
<td>Wisr (ASX:WZR)</td>
<td>10.2%</td>
<td>96.3%</td>
</tr>
<tr>
<td>Titomic (ASX:TTT)</td>
<td>14.8%</td>
<td>74.9%</td>
</tr>
<tr>
<td>Sea Forest (ASX:SEA)</td>
<td>15.1%</td>
<td>92.6%</td>
</tr>
<tr>
<td>Pointerra (ASX:3DP)</td>
<td>19.8%</td>
<td>110.3%</td>
</tr>
<tr>
<td>Newfield Resources (ASX:NWF)</td>
<td>31.5%</td>
<td>72.1%</td>
</tr>
<tr>
<td>IperionX (ASX:IPX)</td>
<td>17.1%</td>
<td>94.9%</td>
</tr>
<tr>
<td>Emerald Resources (ASX:EMR)</td>
<td>18.4%</td>
<td>43%</td>
</tr>
<tr>
<td>Echo IQ (ASX:EIQ)</td>
<td>19%</td>
<td>51.4%</td>
</tr>
<tr>
<td>BlinkLab (ASX:BB1)</td>
<td>32.1%</td>
<td>101.4%</td>
</tr>
<tr>
<td>Adveritas (ASX:AV1)</td>
<td>18.4%</td>
<td>96.8%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們內部持股比例高的快速成長 ASX 公司篩選器中的 111 只股票的完整列表。</p>
<p>讓我們從我們的專業篩選器中發現一些寶藏。</p>
<h2>Clinuvel Pharmaceuticals (ASX:CUV)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Clinuvel Pharmaceuticals Limited 是一家生物製藥公司，開發和商業化針對遺傳、代謝、系統性和危及生命的疾病的治療方案，業務覆蓋澳大利亞、歐洲、美國、瑞士及國際市場，市值為 6.255 億澳元。</p>
<p><strong>運營：</strong> 該公司在生物製藥領域的收入為 9502 萬澳元，專注於多個地區的各種疾病治療。</p>
<p><strong>內部持股比例：</strong> 10.3%</p>
<p>Clinuvel Pharmaceuticals 有望實現強勁增長，預計年收益增長 23.9%，超過澳大利亞市場。儘管預計股本回報率較低，為 18.8%，但 Clinuvel 的收入預計將以每年 22% 的速度增長，超過市場平均水平。該公司的交易價格顯著低於其估計的公允價值，並保持對收購的嚴格控制，專注於符合其風險調整回報標準的北美機會，同時確保運營韌性和戰略資本部署。</p>
<ul>
<li>通過閲讀我們的分析師估計報告，深入瞭解 Clinuvel Pharmaceuticals 的表現。</li>
<li>根據我們的估值報告，Clinuvel Pharmaceuticals 的股價可能偏低。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8fdbe90e-88da-4878-b646-8c5610ec3e4c/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8fdbe90e-88da-4878-b646-8c5610ec3e4c/chart/ownership-breakdown"/></p>
<p>截至 2025 年 12 月的 ASX:CUV 持股結構</p>
<h2>Regis Healthcare (ASX:REG)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Regis Healthcare Limited 在澳大利亞提供住宅養老服務，市值為 21 億澳元。</p>
<p><strong>運營：</strong> 該公司在住宅養老、家庭護理和退休生活服務方面的收入為 11.6 億澳元。</p>
<p><strong>內部持股比例：</strong> 38.6%</p>
<p>Regis Healthcare 正在尋求戰略收購以擴展其投資組合，目標是在 2028 年前達到 10,000 張牀位。該公司的交易價格顯著低於其估計的公允價值，預計年收入增長 8.2%，超過澳大利亞市場。儘管預計收益將以每年 18.6% 的速度強勁增長，但仍低於重要水平。儘管有大量一次性項目影響財務結果，Regis 的股本回報率預計在三年內將非常高。</p>
<ul>
<li>通過我們的綜合分析師估計報告，深入瞭解 Regis Healthcare 的複雜情況。</li>
<li>在審查我們的最新估值報告後，Regis Healthcare 的股價可能過於悲觀。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/03541fc6-4c52-491d-a42d-0c4b1d7681ae/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/03541fc6-4c52-491d-a42d-0c4b1d7681ae/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 12 月的 ASX:REG 收益和收入增長</p>
<h2>Regal Partners (ASX:RPL)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Regal Partners Limited 是一傢俬營對沖基金贊助商，市值為 11.8 億澳元。</p>
<p><strong>運營：</strong> 該公司的收入主要來自投資管理服務，金額為 2.4545 億澳元。</p>
<p><strong>內部持股比例：</strong> 23.8%</p>
<p>Regal Partners 處於增長狀態，預計年收入將增長 15.9%，超過澳大利亞市場的平均水平。該公司的收益預計將以每年 31.51% 的速度顯著增長，也超出市場預期。儘管交易價格顯著低於其估計的公允價值 42.2%，但利潤率已從去年的水平下降。儘管預計其股本回報率在三年內將較低，但內部持股比例仍然較高，且近期沒有重大交易活動。</p>
<ul>
<li>通過我們的完整分析未來增長報告深入瞭解 Regal Partners。</li>
<li>根據我們最近的估值報告，Regal Partners 的交易價格可能低於其估計價值。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3a811177-0426-4731-bd9f-cb3e6afffa07/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3a811177-0426-4731-bd9f-cb3e6afffa07/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 12 月的 ASX:RPL 收益和收入增長</p>
<h2>接下來該怎麼辦？</h2>
<ul>
<li>解鎖更多寶藏！我們的內部持股比例高的快速成長 ASX 公司篩選器為您挖掘了 108 家公司供您探索。點擊這裏揭示我們精心策劃的 111 家快速成長 ASX 公司列表。</li>
<li>想要探索一些替代方案？發現 16 家在 COVID 後生存並蓬勃發展的公司，具備應對特朗普關税的正確條件。</li>
</ul>
<p><em>這篇來自 Simply Wall St 的文章是一般性的。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不旨在提供財務建議。</strong> 它不構成買賣任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有預測的收入和收益增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>
<p>國防和災難的移動基礎設施</p>
<p>下一波機器人技術不是類人型的。它是完全自主的塔，在 30 分鐘內提供 5G、ISR 和雷達，隨時隨地。</p>
<p>在下一輪合同之前獲取投資者簡報</p>
<p>由 CiTech 贊助</p>

皇庭智家

<p>隨着 2025 年的結束，儘管華爾街創下新高，澳大利亞市場卻出現小幅下跌，投資者開始獲利了結。高內部持股的成長型公司被強調為具有吸引力的投資機會。值得注意的公司包括 Wisr（10.2% 的內部持股，96.3% 的收益增長）、Titomic（14.8%，74.9%）和 Clinuvel Pharmaceuticals（10.3%，23.9% 的年增長）。Regis Healthcare（38.6% 的持股）計劃到 2028 年實現 10,000 張牀位，而 Regal Partners（23.8%）則預計將實現顯著的收益增長。文章強調了這些公司在市場波動中的潛力，呼籲進一步探索高內部持股的股票</p>

<p>As the Australian market approaches the end of 2025, it appears to be in a reflective mood with a slight dip as investors engage in profit-taking before the holiday break, despite Wall Street's indices nearing record highs. In this environment, growth companies with high insider ownership can present appealing opportunities due to their potential for alignment between management and shareholder interests.</p>
<div class="lb-trans"><p>隨着澳大利亞市場接近 2025 年底，儘管華爾街的指數接近歷史高點，但市場似乎處於反思的狀態，投資者在假期前進行獲利了結，導致市場略有下滑。在這種環境下，內部持股比例高的成長型公司可能會提供吸引人的機會，因為它們在管理層與股東利益之間的潛在一致性。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership In Australia</h3>
<div class="lb-trans"><h3>澳大利亞內部持股比例高的十大成長型公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>Wisr (ASX:WZR)</td>
<td>10.2%</td>
<td>96.3%</td>
</tr>
<tr>
<td>Titomic (ASX:TTT)</td>
<td>14.8%</td>
<td>74.9%</td>
</tr>
<tr>
<td>Sea Forest (ASX:SEA)</td>
<td>15.1%</td>
<td>92.6%</td>
</tr>
<tr>
<td>Pointerra (ASX:3DP)</td>
<td>19.8%</td>
<td>110.3%</td>
</tr>
<tr>
<td>Newfield Resources (ASX:NWF)</td>
<td>31.5%</td>
<td>72.1%</td>
</tr>
<tr>
<td>IperionX (ASX:IPX)</td>
<td>17.1%</td>
<td>94.9%</td>
</tr>
<tr>
<td>Emerald Resources (ASX:EMR)</td>
<td>18.4%</td>
<td>43%</td>
</tr>
<tr>
<td>Echo IQ (ASX:EIQ)</td>
<td>19%</td>
<td>51.4%</td>
</tr>
<tr>
<td>BlinkLab (ASX:BB1)</td>
<td>32.1%</td>
<td>101.4%</td>
</tr>
<tr>
<td>Adveritas (ASX:AV1)</td>
<td>18.4%</td>
<td>96.8%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股比例</strong></td>
<td><strong>收益增長</strong></td>
</tr>
<tr>
<td>Wisr (ASX:WZR)</td>
<td>10.2%</td>
<td>96.3%</td>
</tr>
<tr>
<td>Titomic (ASX:TTT)</td>
<td>14.8%</td>
<td>74.9%</td>
</tr>
<tr>
<td>Sea Forest (ASX:SEA)</td>
<td>15.1%</td>
<td>92.6%</td>
</tr>
<tr>
<td>Pointerra (ASX:3DP)</td>
<td>19.8%</td>
<td>110.3%</td>
</tr>
<tr>
<td>Newfield Resources (ASX:NWF)</td>
<td>31.5%</td>
<td>72.1%</td>
</tr>
<tr>
<td>IperionX (ASX:IPX)</td>
<td>17.1%</td>
<td>94.9%</td>
</tr>
<tr>
<td>Emerald Resources (ASX:EMR)</td>
<td>18.4%</td>
<td>43%</td>
</tr>
<tr>
<td>Echo IQ (ASX:EIQ)</td>
<td>19%</td>
<td>51.4%</td>
</tr>
<tr>
<td>BlinkLab (ASX:BB1)</td>
<td>32.1%</td>
<td>101.4%</td>
</tr>
<tr>
<td>Adveritas (ASX:AV1)</td>
<td>18.4%</td>
<td>96.8%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 111 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們內部持股比例高的快速成長 ASX 公司篩選器中的 111 只股票的完整列表。</p>
</div><p>Let's uncover some gems from our specialized screener.</p>
<div class="lb-trans"><p>讓我們從我們的專業篩選器中發現一些寶藏。</p>
</div><h2>Clinuvel Pharmaceuticals (ASX:CUV)</h2>
<div class="lb-trans"><h2>Clinuvel Pharmaceuticals (ASX:CUV)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Clinuvel Pharmaceuticals Limited is a biopharmaceutical company that develops and commercializes treatments for genetic, metabolic, systemic, and life-threatening disorders across Australia, Europe, the United States, Switzerland, and internationally with a market cap of A$625.50 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Clinuvel Pharmaceuticals Limited 是一家生物製藥公司，開發和商業化針對遺傳、代謝、系統性和危及生命的疾病的治療方案，業務覆蓋澳大利亞、歐洲、美國、瑞士及國際市場，市值為 6.255 億澳元。</p>
</div><p><strong>Operations:</strong> The company generates revenue of A$95.02 million from its biopharmaceutical sector, focusing on treatments for various disorders across multiple regions.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司在生物製藥領域的收入為 9502 萬澳元，專注於多個地區的各種疾病治療。</p>
</div><p><strong>Insider Ownership:</strong> 10.3%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 10.3%</p>
</div><p>Clinuvel Pharmaceuticals is poised for robust growth, with earnings forecast to rise 23.9% annually, outpacing the Australian market. Despite a projected low Return on Equity of 18.8%, Clinuvel's revenue is expected to grow at 22% per year, surpassing market averages. The company trades significantly below its estimated fair value and maintains a disciplined approach to acquisitions, focusing on North American opportunities that align with its risk-adjusted return criteria while ensuring operational resilience and strategic capital deployment.</p>
<div class="lb-trans"><p>Clinuvel Pharmaceuticals 有望實現強勁增長，預計年收益增長 23.9%，超過澳大利亞市場。儘管預計股本回報率較低，為 18.8%，但 Clinuvel 的收入預計將以每年 22% 的速度增長，超過市場平均水平。該公司的交易價格顯著低於其估計的公允價值，並保持對收購的嚴格控制，專注於符合其風險調整回報標準的北美機會，同時確保運營韌性和戰略資本部署。</p>
</div><ul>
<li>Get an in-depth perspective on Clinuvel Pharmaceuticals' performance by reading our analyst estimates report here.</li>
<li>According our valuation report, there's an indication that Clinuvel Pharmaceuticals' share price might be on the cheaper side.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過閲讀我們的分析師估計報告，深入瞭解 Clinuvel Pharmaceuticals 的表現。</li>
<li>根據我們的估值報告，Clinuvel Pharmaceuticals 的股價可能偏低。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8fdbe90e-88da-4878-b646-8c5610ec3e4c/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/8fdbe90e-88da-4878-b646-8c5610ec3e4c/chart/ownership-breakdown"/></p>
<p>ASX:CUV Ownership Breakdown as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 ASX:CUV 持股結構</p>
</div><h2>Regis Healthcare (ASX:REG)</h2>
<div class="lb-trans"><h2>Regis Healthcare (ASX:REG)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Regis Healthcare Limited provides residential aged care services in Australia and has a market cap of A$2.10 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Regis Healthcare Limited 在澳大利亞提供住宅養老服務，市值為 21 億澳元。</p>
</div><p><strong>Operations:</strong> The company generates revenue of A$1.16 billion from its residential aged care, home care, and retirement living services in Australia.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司在住宅養老、家庭護理和退休生活服務方面的收入為 11.6 億澳元。</p>
</div><p><strong>Insider Ownership:</strong> 38.6%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 38.6%</p>
</div><p>Regis Healthcare is targeting strategic acquisitions to expand its portfolio and aims for 10,000 beds by 2028. The company is trading significantly below its estimated fair value and expects revenue growth of 8.2% annually, outpacing the Australian market. Although earnings are forecast to grow at a robust 18.6% annually, they remain below significant levels. Despite large one-off items affecting financial results, Regis's Return on Equity is projected to be very high in three years' time.</p>
<div class="lb-trans"><p>Regis Healthcare 正在尋求戰略收購以擴展其投資組合，目標是在 2028 年前達到 10,000 張牀位。該公司的交易價格顯著低於其估計的公允價值，預計年收入增長 8.2%，超過澳大利亞市場。儘管預計收益將以每年 18.6% 的速度強勁增長，但仍低於重要水平。儘管有大量一次性項目影響財務結果，Regis 的股本回報率預計在三年內將非常高。</p>
</div><ul>
<li>Navigate through the intricacies of Regis Healthcare with our comprehensive analyst estimates report here.</li>
<li>Upon reviewing our latest valuation report, Regis Healthcare's share price might be too pessimistic.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過我們的綜合分析師估計報告，深入瞭解 Regis Healthcare 的複雜情況。</li>
<li>在審查我們的最新估值報告後，Regis Healthcare 的股價可能過於悲觀。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/03541fc6-4c52-491d-a42d-0c4b1d7681ae/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/03541fc6-4c52-491d-a42d-0c4b1d7681ae/chart/earnings-and-revenue-growth"/></p>
<p>ASX:REG Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 ASX:REG 收益和收入增長</p>
</div><h2>Regal Partners (ASX:RPL)</h2>
<div class="lb-trans"><h2>Regal Partners (ASX:RPL)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Regal Partners Limited is a privately owned hedge fund sponsor with a market capitalization of A$1.18 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Regal Partners Limited 是一傢俬營對沖基金贊助商，市值為 11.8 億澳元。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from the provision of investment management services, amounting to A$245.45 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司的收入主要來自投資管理服務，金額為 2.4545 億澳元。</p>
</div><p><strong>Insider Ownership:</strong> 23.8%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 23.8%</p>
</div><p>Regal Partners is positioned for growth, with revenue expected to increase by 15.9% annually, surpassing the Australian market's average. The company's earnings are forecast to grow significantly at 31.51% per year, also exceeding market expectations. Despite trading at a substantial discount of 42.2% below its estimated fair value, profit margins have declined from last year’s levels. While its Return on Equity is projected to be low in three years, insider ownership remains high without recent substantial trading activity.</p>
<div class="lb-trans"><p>Regal Partners 處於增長狀態，預計年收入將增長 15.9%，超過澳大利亞市場的平均水平。該公司的收益預計將以每年 31.51% 的速度顯著增長，也超出市場預期。儘管交易價格顯著低於其估計的公允價值 42.2%，但利潤率已從去年的水平下降。儘管預計其股本回報率在三年內將較低，但內部持股比例仍然較高，且近期沒有重大交易活動。</p>
</div><ul>
<li>Delve into the full analysis future growth report here for a deeper understanding of Regal Partners.</li>
<li>In light of our recent valuation report, it seems possible that Regal Partners is trading behind its estimated value.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過我們的完整分析未來增長報告深入瞭解 Regal Partners。</li>
<li>根據我們最近的估值報告，Regal Partners 的交易價格可能低於其估計價值。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3a811177-0426-4731-bd9f-cb3e6afffa07/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/3a811177-0426-4731-bd9f-cb3e6afffa07/chart/earnings-and-revenue-growth"/></p>
<p>ASX:RPL Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 ASX:RPL 收益和收入增長</p>
</div><h2>Where To Now?</h2>
<div class="lb-trans"><h2>接下來該怎麼辦？</h2>
</div><ul>
<li>Unlock more gems! Our Fast Growing ASX Companies With High Insider Ownership screener has unearthed 108 more companies for you to explore.Click here to unveil our expertly curated list of 111 Fast Growing ASX Companies With High Insider Ownership.</li>
<li>Want To Explore Some Alternatives? Uncover 16 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖更多寶藏！我們的內部持股比例高的快速成長 ASX 公司篩選器為您挖掘了 108 家公司供您探索。點擊這裏揭示我們精心策劃的 111 家快速成長 ASX 公司列表。</li>
<li>想要探索一些替代方案？發現 16 家在 COVID 後生存並蓬勃發展的公司，具備應對特朗普關税的正確條件。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p><em>這篇來自 Simply Wall St 的文章是一般性的。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不旨在提供財務建議。</strong> 它不構成買賣任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有預測的收入和收益增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>國防和災難的移動基礎設施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波機器人技術不是類人型的。它是完全自主的塔，在 30 分鐘內提供 5G、ISR 和雷達，隨時隨地。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一輪合同之前獲取投資者簡報</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>由 CiTech 贊助</p>
</div>

2025 年 12 月 ASX 成長股中擁有高內部持股的公司